<img alt="" src="https://secure.perk0mean.com/184504.png" style="display:none;">
Skip to content
Request a Demo

Posts by Amy Ripston

August 24, 2022
Real-time drug tracking is set to become an industry standard

Be sure to listen to the January 2022 episode of the Trial Trends podcast, "3 Trends That Will Shape 2022" for more insights for 2022 and beyond.

Learn More
June 23, 2022
3 Simple Steps to Manage Multiple Protocol Versions in a Single Study

Managing protocol versions at the site level and the broader protocol amendment at the sponsor level go hand-in-hand. Neither is simple, but both sides of the equation must...

Learn More
June 22, 2022
Master Protocol Studies – A Map to an Unknown Destination

Learn More

About the Author

Amy Ripston, 4G Clinical Vice President of Marketing, has over 20 years of B2B experience, of which she spent 9 years in the bio/pharmaceutical industry. Amy has a knack for identifying market trends, synthesizing content, engaging thought leaders, and connecting businesses with innovative solutions.

Filter by Topic

July 8, 2022
The Rising Complexity of Ancillary Management
Read More
September 15, 2021
A Metastatic Breast Cancer (MBC) Patient’s Journey to ‘No Active Disease’
Read More
September 1, 2021
A Rare Disease Patient Sheds Light on Journey for Treatment
Read More
September 30, 2020
Is Direct-to-Patient (DtP) the Tip of the Virtual Trial Iceberg?
Read More
September 24, 2020
5 Questions You Never Ask Your RTSM Vendor, But Should
Read More
May 29, 2020
5 Supply Chain Impacts Resulting from Master Protocol Amendments – And How to Prepare
Read More
May 15, 2020
3 Simple Steps to Manage Multiple Protocol Versions in a Single Study
Read More
May 7, 2020
Master Protocol Studies – A Map to an Unknown Destination
Read More
March 23, 2020
The Site Perspective: COVID-19 and the movement towards Direct-to-Patient trials
Read More